Thyrocare Technologies Limited has successfully completed the acquisition of the diagnostic and pathological services business of Vimta Labs Limited. The acquisition was finalized on October 11, 2024, following the pre-determined conditions laid out in the Business Transfer Agreement (BTA) between the two companies.
As per the agreement, Thyrocare has commenced operations of the newly acquired business on a going-concern basis starting from the same day. This strategic acquisition strengthens Thyrocare’s position in the diagnostics industry, expanding its capabilities and service offerings.
The completion of the acquisition was confirmed in a stock exchange filing, providing clarity on the transition and the future direction of the company’s operations.
